Drugs & Aging

, Volume 23, Issue 11, pp 887–896

Risperidone for the Treatment of Neuropsychiatric Features in Dementia

Review Article

DOI: 10.2165/00002512-200623110-00004

Cite this article as:
Burns, A. & De Deyn, P.P. Drugs Aging (2006) 23: 887. doi:10.2165/00002512-200623110-00004

Abstract

Neuropsychiatric features of dementia are a common and significant burden on patients and their carers. Management usually involves a combination of pharmacological and non-pharmacological approaches. Antipsychotics are the cornerstone of treatment; among the atypical antipsychotics, risperidone is the most studied. Several trials have confirmed the efficacy of risperidone in the treatment of neuropsychiatric features in dementia, especially for agitation and psychosis. Recent concerns over an increased cerebrovascular adverse event profile and overall mortality with use of antipsychotics have emphasised the need for a risk-benefit analysis for individual demented patients being treated for neuropsychiatric features of their disease.

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Education and Research Centre, Wythenshawe HospitalUniversity of ManchesterManchesterUK
  2. 2.Department of Neurology, Memory Clinic, Middelheim HospitalZNA, University of AntwerpWilrijk-AntwerpBelgium

Personalised recommendations